Vertex sinks after FDA freezes portion of hepatitis drug trial

Investors pounded Vertex Pharmaceuticals in after-hours trading Thursday after the company announced that the U.S. Food and Drug Administration had placed a partial hold on a drug trial for a hepatitis C therapy that may have contributed to liver toxicity in some patients.

http://www.bizjournals.com/boston/blog/mass_roundup/2013/07/vertex-sinks-after-fda-freezes-portion.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_boston+%28Boston+Business+Journal%29